AstraZeneca strikes broad alliance for Amgen's clinical-stage inflammation portfolio
This article was originally published in Scrip
Executive Summary
Amgen will get $50 million upfront from AstraZeneca under a collaboration agreement to jointly develop and commercialise five monoclonal antibodies from Amgen's clinical inflammation portfolio, which will allow the US biotechnology company to refocus some of its resources on earlier stage programmes.
You may also be interested in...
Q&A: SVP Elliott Levy On Amgen R&D's 'Singular Focus On Innovation'
Scrip spoke with Levy, senior vice president of global development, about the company's novel candidates for cardiovascular and inflammatory diseases and cancer, including modalities outside of its primary focus on biologics and small molecules.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.